Slide 1: A clinical-stage drug development business: Investor Update
For personal use only A clinical-stage drug development business Investor Update Dr James Williams February 2016
Slide 2: Agenda today
Agenda today For personal use only 1. Who we are 2. Snapshot and financials 3. Market and long-term growth strategy 4. Summary and outlook 2
Slide 3: Quick overview
Quick overview For personal use only Key Assets Corporate Snapshot Who we are: A clinical-stage drug development ASX Code: DXB (formerly SBN) company focused on commercialising new Share Price: $.006 therapeutic treatments identified using our Market cap: $8.4m proprietary drug discovery platform. C
Slide 4: The Dimerix drug paradigm
The Dimerix drug paradigm G Protein Coupled Receptors (GPCRs) – the most relevant molecules in drug For personal use only development today • ≈ 50% of all successful drugs currently in human medicine target GPCRs • Act as single units (monomers) or in pairs (heterodimers) New GRCR A Drug B pharmacol
Slide 5: Dimerix lead drug program
Dimerix lead drug program For personal use only Chronic Kidney Disease (CKD) • A global health problem leading to kidney failure, cardiovascular disease and premature death. • Currently affects an estimated 26 million people in the US Focal Segmental Glomerulosclerosis (FSGS) • Scarring of kidney (g
Slide 6: DMX-200 – Lead therapy
DMX-200 – Lead therapy Dimerix identified DMX-200 using Receptor-HIT: For personal use only A new therapeutic approach to Chronic Kidney Disease • Combination therapy comprising Irbesartan + Propagermanium • Targets GPCR heterodimer: Angiotensin type 1 receptor (AT1) & Chemokine receptor 2 (CCR2) •
Slide 7: DMX-200 – Clinical study progress
DMX-200 – Clinical study progress For personal use only Study Aim • Treatment of proteinuria in chronic kidney disease (CKD) patients Study design • Fixed dose combination of Irbesartan + Propagermanium • Enrolment: Up to 60 patients in two parts: • Part A: Dose escalation – up to five doses x one m
Slide 8: Market interest in CKD treatments
Market interest in CKD treatments For personal use only • Acthar gel (injection only, steroid) • Phase I asset for treating kidney • Completed Phase II for CCX140 fibrosis in diabetic nephropathy – a • Approved in 2011 for treating CCR2 antagonist proteinuria in Nephrotic • Acquired by Shire Syndrom
Slide 9: Market interest in discovery platforms
Market interest in discovery platforms For personal use only • Phase 1b plus multiple pre- • Early phase III and two phase II • Phase III and phase II assets clinical leads assets • GPCR discovery platform • GPCR discovery platform • GPCR discovery platform • Acquired by Celgene Jul 2015 for • Acqui
Slide 10: Pipeline of other therapeutic assets
Pipeline of other therapeutic assets For personal use only DMX-200 • Potential utility in several other therapeutic indications • Pre-clinical animal studies underway for liver disease • Results expected Q3 2016 • Positive data will support initiation of a second human clinical trial Receptor-HIT: A
Slide 11: Summary and outlook
Summary and outlook For personal use only Dimerix: A Clinical stage (Phase II) biotechnology business commercialising new therapies for under-served and unmet medical needs globally Business Model • Experienced management and board • Outsourcing to reduce costs • Focus on US market approvals Mitigat
Slide 12: Further Information
For personal use only Further Information James Williams, Executive Chairman +61 409 050 519 james@dimerix.com Dimerix Limited ACN 001 285 230 www.dimerix.com
Slide 13: Experienced board and management
Experienced board and management For personal use only Executive Chairman: Dr James Williams • 15 years experience starting, funding, running and exiting biotechnology companies BSc(Hons), PhD, MBA • Co-founder of Dimerix and iCeutica (acquired in 2011 and now with 3 FDA drug approvals) • Co-founder
Slide 14: Leading scientific advisors
Leading scientific advisors For personal use only Scientific Advisors: Assoc. Prof Kevin Pfleger • Inventor of Dimerix technology MA, PhD • Head of Molecular Endocrinology and Pharmacology at the Harry Perkins Institute of Medical Research • Leading National Health and Medical Research Council RD Wr
Slide 15: Core Intellectual Property
Core Intellectual Property For personal use only Combination Therapy: PCT Number: AU2012/000014 International Filing 11 January 2012 Date: Status: Granted in Australia, Allowed in the US, examination progressing in EU and Japan Applicant: Dimerix Bioscience Pty Ltd Inventors: PFLEGER, Kevin Donald G